Syed Shah Qadri, MD
Interventional Cardiology · Floral Park, NYNPI 1104040369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $484, 2.2 times the $216 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.
Across 92 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$415
- Abbott$385
- GSK$374
- Bayer$255
- Amgen$251
- AbbVie$226
- plus $905 from 13 others
What the payments were for
- Food & beverage$2,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $415 |
| Abbott | 5 | $385 |
| GSK | 3 | $374 |
| Bayer | 12 | $255 |
| Amgen(2 entities) | 15 | $251 |
| AbbVie | 6 | $226 |
| Novo Nordisk | 4 | $179 |
| Pfizer | 7 | $162 |
| Merck | 5 | $134 |
| Lilly USA, LLC | 6 | $110 |
| Novartis | 3 | $73 |
| Amarin Pharma, Inc. | 4 | $69 |
| Kowa Pharmaceuticals America, Inc. | 3 | $54 |
| Johnson & Johnson | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assurity Pacemaker$134
- Fortify Assura$125
- BENLYSTA$125
- Ozempic$125
- BREZTRI$125
- NUCALA$125
- ANORO ELLIPTA$125
- FARXIGA$112
How this compares
$2,812 in reported general payments places this provider in the 25th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $64,799 |
| JardianceEmpagliflozin | 43 | $50,593 |
| OzempicSemaglutide | 38 | $50,012 |
| EntrestoSacubitril/Valsartan | 42 | $46,742 |
| JanuviaSitagliptin Phosphate | 20 | $28,448 |
| BrilintaTicagrelor | 33 | $26,048 |
| XareltoRivaroxaban | 31 | $25,554 |
| FarxigaDapagliflozin Propanediol | 15 | $22,319 |
| Repatha PushtronexEvolocumab | 22 | $20,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,804 |
| Praluent PenAlirocumab | 29 | $15,762 |
| Metoprolol Succinate | 219 | $3,614 |
| Atorvastatin Calcium | 228 | $2,113 |
| ClopidogrelClopidogrel Bisulfate | 83 | $1,100 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 50 | $1,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $162 | $64,79976 claims |
| Novo NordiskOzempic | $179 | $50,01238 claims |
| AstraZenecaBrilinta, Farxiga | $415 | $48,36748 claims |
| NovartisEntresto | $73 | $46,74242 claims |
| MerckJanuvia | $134 | $28,44820 claims |
| Johnson & JohnsonXarelto | $29 | $25,55431 claims |
| GSKTrelegy Ellipta | $374 | $18,80428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Floral Park
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- David CohenRoslyn$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.